Infliximab & Ulcerative colitis (UC)

Infliximab is approved by the FDA and EMA for treating moderate to severe ulcerative colitis (UC) in patients who do not respond adequately to conventional therapy or are intolerant to such treatments. It was the first biological agent approved for UC, with its use supported by data from randomized controlled trials and extensive clinical experience (1, 2, 3, 4).

References:

(1) Papamichael et al. 2019 Ther Adv Chronic Dis 10: 2040622319838443
(2) Herfarth et al. 2015 Clin Gastroenterol Hepatol 13(2): 336-8
(3) Akiho et al. 2…